Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs

被引:23
|
作者
Milo, Ron [1 ]
机构
[1] Ben Gurion Univ Negev, Dept Neurol, Barzilai Med Ctr, Fac Hlth Sci, Ashqelon, Israel
关键词
disability; disease activity; disease-modifying therapy; MRI; multiple sclerosis; no evidence of disease activity; prognostic factors; risk-benefit; therapy; SUBCUTANEOUS INTERFERON BETA-1A; PLACEBO-CONTROLLED PHASE-3; GLATIRAMER ACETATE; DOUBLE-BLIND; ORAL TERIFLUNOMIDE; INTRAMUSCULAR INTERFERON; DISEASE-ACTIVITY; CONTROLLED TRIAL; NATURAL-HISTORY; DEMYELINATING EVENT;
D O I
10.1517/14656566.2015.1002769
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS of a putative autoimmune origin characterized by neurologic dysfunction disseminated in space and time due to demyelination and axonal loss that results in progressive disability. Recent advances in understanding the immune pathogenesis of the disease resulted in the introduction of numerous effective immunomodulatoty drugs having diverse mechanisms of action, modes of administration and risk-benefit profiles. This results in more complex albeit more promising treatment selection and choices. Areas covered: The epidemiology, clinical features, pathogenesis and diagnosis of the disease are discussed. The mode of action and main characteristics of current immunomodulatory drugs for MS and their place in the therapeutic algorithm of the disease based on evidence from clinical trials are described. Speculation on new paradigms, treatment goals and outcome measures aimed at improving the landscape of MS treatment is presented. Expert opinion: Multiple disease, drug and patient-related factors should be taken into consideration when selecting the appropriate drug and treatment strategy to the appropriate patient, thus paving the road for personalized medicine in MS.
引用
收藏
页码:659 / 673
页数:15
相关论文
共 50 条
  • [41] Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey
    Sorensen, PS
    Koch-Henriksen, N
    Ravnborg, M
    Frederiksen, JL
    Jensen, K
    Heltberg, A
    Schaldemose, H
    Deth, S
    Kristensen, O
    Worm, M
    Stenager, E
    Hansen, HJ
    Sivertsen, B
    Torring, J
    MULTIPLE SCLEROSIS, 2006, 12 (03): : 253 - 264
  • [42] Autoimmune hepatitis in patients with multiple sclerosis: The role of immunomodulatory treatment
    Rigopoulou, Eirini, I
    Gyftaki, Sofia
    Arvaniti, Pinelopi
    Tsimourtou, Vana
    Koukoulis, George K.
    Hadjigeorgiou, Georgios
    Dalekos, George N.
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2019, 43 (03) : E25 - E32
  • [43] IS SECOND-LINE IMMUNOMODULATORY TREATMENT EFFECTIVE IN MULTIPLE SCLEROSIS?
    Racz Lilla
    Berenyi Ervin
    Barsi Peter
    Bernath David
    Csepany Tunde
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2017, 70 (7-8): : 275 - 283
  • [44] Effect of immunomodulatory treatment of multiple sclerosis on lymphocyte surface immunomarkers
    Michalowska-Wender, G
    Losy, J
    Wender, M
    Januszkiewicz-Lewandowska, D
    Nowak, J
    POLISH JOURNAL OF PHARMACOLOGY, 2003, 55 (05): : 877 - 880
  • [45] Efficacy and Safety of Natalizumab in Multiple Sclerosis Patients Pretreated with Immunomodulatory and Immunosuppressive Drugs
    Mueller, Ulrich
    Pagenkopf, Claudia
    Asimiadou, Stiliani
    Haas, Judith
    NEUROLOGY, 2009, 72 (11) : A360 - A360
  • [46] Immunomodulatory networks in multiple sclerosis
    Ntranos, Achillefs
    Lee, Brian
    Xie, Hui
    Rockoff, Jonathan
    Brandstadter, Rachel
    Kim-Schulze, Seunghee
    Lublin, Fred
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [47] Immunomodulatory therapy of multiple sclerosis
    Weber, F
    NERVENHEILKUNDE, 2000, 19 (06) : 310 - 315
  • [48] Current treatment options in multiple sclerosis
    Boissy A.
    Fox R.J.
    Current Treatment Options in Neurology, 2007, 9 (3) : 176 - 186
  • [49] Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
    Landgren, Ola
    Sonneveld, Pieter
    Jakubowiak, Andrzej
    Mohty, Mohamad
    Iskander, Karim S.
    Mezzi, Khalid
    Siegel, David S.
    LEUKEMIA, 2019, 33 (09) : 2127 - 2143
  • [50] Audit of thromboprophylaxis for patients with multiple myeloma on treatment with immunomodulatory drugs
    Kumari, A.
    Man, R.
    Gardner, C.
    Paneesha, S.
    Kishore, B.
    Pratt, G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 90 - 90